A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate

Expert Opin Pharmacother. 2009 Dec;10(17):2935-7. doi: 10.1517/14656560903418467.

Abstract

A new drug combination regimen, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate (TDF), is described for the treatment of HIV-1 infection. This new drug combination regimen is applicable to the treatment of drug-naïve HIV-1-infected patients. It extends the use of the drug combinations to a new class of anti-HIV drugs, i.e. raltegravir, targeted at a new site in the HIV-1 replicative cycle, namely the HIV-1 integrase. This opens new perspectives for the design of multiple drug combination regimens targeting different enzymes involved in HIV-1 replication, i.e. integrase and reverse transcriptase. These multiple (triple or quadruple) drug combinations should be aimed at once daily dosing.

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Drug Therapy, Combination
  • Emtricitabine
  • HIV Infections / drug therapy*
  • HIV-1
  • Humans
  • Organophosphonates / administration & dosage
  • Organophosphonates / therapeutic use*
  • Pyrrolidinones / administration & dosage
  • Pyrrolidinones / therapeutic use*
  • Raltegravir Potassium
  • Tenofovir

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Pyrrolidinones
  • Deoxycytidine
  • Raltegravir Potassium
  • Tenofovir
  • Emtricitabine
  • Adenine